The DHT Conversation: Hair Loss, Prostate, and the Tradeoff No One Discusses

Dihydrotestosterone is testosterone's more potent cousin. It binds the androgen receptor with 3-5 times greater affinity and drives many of the effects you think of as "male" — beard growth, deepening voice, prostate development during puberty. It also drives male pattern baldness and benign prostatic hyperplasia.

That's the tradeoff. Block DHT and you protect your hairline and slow prostate growth. Block DHT and you potentially affect libido, erectile function, and mood in a subset of men. The drug that does this — finasteride — has been studied more than almost any other men's health medication, and the conversation around it is still a mess.

What DHT Actually Does

Testosterone gets converted to DHT by the enzyme 5-alpha-reductase, of which there are two main subtypes. Type 1 predominates in skin and liver; Type 2 is active in the genitourinary system, including the prostate and hair follicles. The conversion happens locally — DHT in the prostate isn't circulating DHT; it's synthesized on site from testosterone that arrives through the bloodstream.

Circulating DHT is about 10% of circulating testosterone. In target tissues, local DHT concentrations can be 5-10 times higher than circulating testosterone. This is why DHT blockers work so well at the target organs without completely flooring systemic testosterone.

DHT drives:

• Androgen receptor activation (more potent than testosterone)
• Male pattern hair loss (genetically susceptible hair follicles miniaturize under DHT exposure)
• Prostate enlargement over decades, leading to BPH symptoms
• Beard and body hair growth
• Sebum production in skin

Hair Loss: The Finasteride Reality

Finasteride, at 1 mg daily, is FDA-approved for male pattern baldness. It inhibits Type 2 5-alpha-reductase and lowers scalp DHT by about 60-70%. Clinical trial data show roughly 80% of men maintain or regrow hair over 2 years. It doesn't work for everyone and doesn't regrow fully bald scalps, but it's the most effective hair loss drug on the market.

Dutasteride, at 0.5 mg daily, inhibits both Type 1 and Type 2 enzymes, suppressing DHT more completely (>90%). It's FDA-approved for BPH, off-label for hair loss. More effective for hair loss but potentially more side effect risk.

Minoxidil (Rogaine) works by a different mechanism — vasodilation at the follicle — and can be combined with finasteride. The combination outperforms either alone.

The Side Effect Conversation

This is where the discussion gets fraught. The finasteride label mentions sexual side effects: decreased libido (1-2% in trials), erectile dysfunction (1-2%), ejaculation problems. These numbers come from the original Merck trials. In placebo-controlled data, the difference between finasteride and placebo was small — around 1-2 percentage points in most trials.

But online forums are full of men reporting persistent sexual dysfunction, anxiety, and depression that didn't resolve after stopping the drug. This phenomenon is called post-finasteride syndrome (PFS). The medical community's position on PFS is cautious: some cases are real, the prevalence is unclear, and the biological mechanism isn't fully understood.

What the evidence actually shows:

• A small minority of men develop sexual side effects on finasteride (single-digit percent in controlled trials)
• In most men, side effects resolve on stopping the drug
• A smaller subset reports persistent symptoms (PFS) — this is reported but prevalence is debated
• Depression and anxiety signals exist in pharmacovigilance data; 2017 JAMA Dermatology study found roughly doubled depression risk vs non-users
• Fertility: finasteride can reduce sperm count in some men; usually reverses on stopping

The honest summary: most men do fine on finasteride. A meaningful minority do not, and the impact on them can be significant. The risk-benefit calculation depends on how bothered you are by hair loss vs how much you're willing to gamble.

Topical Finasteride: A Middle Ground?

Applied topically to the scalp, finasteride reduces scalp DHT with much lower systemic absorption. Several studies have shown topical formulations achieve similar scalp DHT reduction with lower circulating DHT suppression and fewer reported systemic side effects. The evidence base is smaller than oral, and it's not FDA-approved in the US, but many telehealth services now offer it through compounding pharmacies.

Topical is the option I'd suggest people consider before oral — talk to your doctor about whether it's appropriate for you. Lower systemic exposure, potentially similar local efficacy, less commitment-level intervention.

Prostate: The BPH Story

Benign prostatic hyperplasia affects roughly 50% of men by age 60 and 90% by age 85. Symptoms: urinary frequency, urgency, weak stream, incomplete emptying, nocturia. Not cancer, but quality-of-life damaging and increasingly common with age.

5-alpha-reductase inhibitors (finasteride 5 mg for BPH, or dutasteride 0.5 mg) reduce prostate volume by 20-30% over 12-24 months. Symptom improvement is modest but real. They're usually combined with alpha-blockers like tamsulosin for faster symptom relief (alpha-blockers relax muscle tone in the prostate and bladder neck).

The BPH dose of finasteride is 5x the hair loss dose — 5 mg vs 1 mg. Side effect risk scales somewhat with dose, though not linearly. Many men tolerate 1 mg for hair loss but have issues at 5 mg.

The PSA Interaction

Finasteride and dutasteride lower PSA by roughly 50%. A man taking finasteride whose PSA reads 2.0 actually has an "effective" PSA of 4.0 — in the concerning range. This matters for prostate cancer screening. Any urologist should double your PSA value when interpreting labs on a 5-ARI. Men unaware of this correction have been missed for prostate cancer because their PSA "looked normal" on the medication.

If you're on finasteride for hair loss and getting PSA tested, make sure the interpretation accounts for it.

Prostate Cancer: A Complicated Signal

The PCPT trial from 2003 found finasteride reduced prostate cancer incidence by 25% over 7 years — but also found a slight increase in high-grade cancers in the treatment group. Subsequent analysis suggested this was partly an artifact (finasteride shrinks prostates, making cancers easier to detect and biopsy). The FDA revised labeling to note the signal.

Current best interpretation: 5-ARIs reduce overall prostate cancer diagnosis but may slightly increase detection of high-grade tumors. The clinical implication is unclear. Most urologists don't prescribe finasteride for cancer prevention because of this ambiguity.

Who Should Take a 5-ARI

For hair loss: men bothered enough by baldness to accept 1-3% risk of sexual side effects, who understand the medication is a long-term (potentially lifelong) commitment, and who've considered alternatives (minoxidil alone, hair transplant, acceptance).

For BPH: men with bothersome urinary symptoms, particularly with larger prostates (over 40 mL), where the 5-ARI offers benefits beyond what alpha-blockers alone provide. Usually prescribed by urologists, not primary care.

Not recommended: men planning near-term conception (finasteride can affect sperm parameters), men with history of depression (signal is there even if modest), men who can't commit to consistent use (intermittent use means side effect risk without benefit).

Natural DHT Blockers

Saw palmetto is the most popular "natural" 5-ARI. In head-to-head trials, it's less effective than finasteride but possibly not completely useless. Meta-analyses of BPH trials show small symptom improvements over placebo, but not at the level of pharmaceutical 5-ARIs. For hair loss, evidence is even weaker.

Pumpkin seed oil has some small trial data for hair loss. Green tea catechins in vitro inhibit 5-AR, with unclear clinical relevance. Zinc deficiency can affect DHT production, but supplementation in non-deficient men doesn't meaningfully change DHT.

None of these will preserve a hairline that finasteride would save. If you want meaningful DHT reduction, the OTC options are not the path.

The Decision Framework

Hair loss is a cosmetic and psychological issue. It's a real issue — men care about it, and that's fine — but it's not a disease. BPH at symptomatic levels is a genuine medical condition. The threshold for medication makes sense to be different.

For hair loss: consider topical minoxidil first. If that's insufficient, consider topical finasteride. If you're willing to take the systemic drug, start at 1 mg (or 0.5 mg every other day) and monitor. Be honest with yourself about side effects; don't push through significant changes.

For BPH: follow your urologist's lead. The risk-benefit calculation is different when you're treating symptoms rather than preventing baldness.

Either way, understand what you're doing to your androgen biology. It's a real tradeoff, not a free win.